NASDAQ:PMN Promis Neurosciences Q2 2025 Earnings Report $9.83 -1.17 (-10.64%) Closing price 04:00 PM EasternExtended Trading$10.07 +0.24 (+2.44%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Promis Neurosciences EPS ResultsActual EPS-$7.25Consensus EPS -$5.50Beat/MissMissed by -$1.75One Year Ago EPSN/APromis Neurosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APromis Neurosciences Announcement DetailsQuarterQ2 2025Date8/13/2025TimeBefore Market OpensConference Call DateWednesday, August 13, 2025Conference Call Time7:00AM ETUpcoming EarningsPromis Neurosciences' Q1 2026 earnings is estimated for Monday, May 11, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, May 13, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Promis Neurosciences Earnings HeadlinesAnalysts Set Promis Neurosciences (NASDAQ:PMN) PT at $42.67May 2, 2026 | americanbankingnews.comProMIS Neurosciences (PMN) price target decreased by 57.76% to 35.06March 28, 2026 | msn.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.May 7 at 1:00 AM | American Alternative (Ad)ProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate HighlightsMarch 25, 2026 | finanznachrichten.deProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate HighlightsMarch 25, 2026 | globenewswire.comProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)March 18, 2026 | globenewswire.comSee More Promis Neurosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Promis Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Promis Neurosciences and other key companies, straight to your email. Email Address About Promis NeurosciencesPromis Neurosciences (NASDAQ:PMN), Inc. is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis. Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation. The company’s pipeline reflects a commitment to addressing unmet needs in neurology by optimizing compound profiles for safety, selectivity and central nervous system penetration. Promis Neurosciences collaborates with academic institutions and industry partners to accelerate its research and development efforts. These strategic alliances support biomarker identification, translational studies and clinical trial design, aiming to streamline candidate advancement and enrich patient selection strategies. The company is headquartered in the United States and its common stock trades on the Nasdaq stock exchange under the symbol PMN.View Promis Neurosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles The AI Fear Around Datadog Stock May Have Been Completely WrongAmprius Technologies Ups the Voltage on Forward OutlookWhy Lam Research Still Looks Like a Buy After a 300% RallyIonQ Just Posted a Breakout Quarter—But 1 Problem RemainsSuper Micro Surges Over 20% as Margins Soar, Sales Fall ShortNuts and Bolts AI Play Gains Momentum: Astera Labs Targets RaisedAnheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Upcoming Earnings AngloGold Ashanti (5/8/2026)Brookfield Asset Management (5/8/2026)Enbridge (5/8/2026)Toyota Motor (5/8/2026)Ubiquiti (5/8/2026)Constellation Energy (5/11/2026)Barrick Mining (5/11/2026)Petroleo Brasileiro S.A.- Petrobras (5/11/2026)Simon Property Group (5/11/2026)SEA (5/12/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
